GSCs interact with non-tumor cells from the tumor microenvironment using the immune cytokine receptors, such as interleukin 6 (IL-6), vascular endothelial (VEGF), and epidermal growth factor (ERGF), notch signaling pathways, and platelet derived growth factor, through which tumor cells avoid the immune response [34]. The gene discussed is VEGFA; the disease is neoplasm.